{"id":"generic-travoprost","safety":{"commonSideEffects":[{"rate":"30-50","effect":"Conjunctival hyperemia (redness)"},{"rate":"10-20","effect":"Iris pigmentation increase"},{"rate":"10-15","effect":"Eyelash growth (hypertrichosis)"},{"rate":"5-15","effect":"Eye irritation/discomfort"},{"rate":"5-10","effect":"Periocular skin pigmentation"}]},"_chembl":{"chemblId":"CHEMBL1200799","moleculeType":"Small molecule","molecularWeight":"500.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Travoprost mimics the action of naturally occurring prostaglandins by activating FP receptors in the eye. This activation enhances drainage of fluid (aqueous humor) through the uveoscleral pathway, the primary drainage route in the eye. The resulting decrease in intraocular pressure helps prevent optic nerve damage and vision loss in glaucoma and ocular hypertension.","oneSentence":"Travoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:31:08.412Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Open-angle glaucoma"},{"name":"Ocular hypertension"}]},"trialDetails":[{"nctId":"NCT02796560","phase":"PHASE4","title":"Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension","status":"COMPLETED","sponsor":"Université de Sherbrooke","startDate":"2016-07-01","conditions":"Glaucoma, Primary Open Angle, Ocular Hypertension","enrollment":76},{"nctId":"NCT03965052","phase":"PHASE1","title":"Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan®","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2019-04-24","conditions":"Glaucoma","enrollment":24}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"TREATMENT FAILURE"}],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Travoprost"],"phase":"marketed","status":"active","brandName":"Generic travoprost","genericName":"Generic travoprost","companyName":"Université de Sherbrooke","companyId":"universit-de-sherbrooke","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Travoprost is a prostaglandin F analog that binds to the prostaglandin F (FP) receptor to increase uveoscleral outflow of aqueous humor, thereby reducing intraocular pressure. Used for Open-angle glaucoma, Ocular hypertension.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}